No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ENTA240517P17500
- 1.85
- 0.000.00%
15min DelayTrading Apr 1 11:23 ET
0.00High0.00Low
0.00Open1.85Pre Close0 Volume3 Open Interest17.50Strike Price0.00Turnover260.68%IV-4.18%PremiumMay 17, 2024Expiry Date4.82Intrinsic Value100Multiplier7DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.7476Delta0.0676Gamma2.37Leverage Ratio-0.1009Theta-0.0026Rho-1.77Eff Leverage0.0058Vega
Intraday
- 5D
- 1D
News
Express News | Enanta Pharmaceuticals Inc : Evercore ISI Cuts Target Price to $30 From $35
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably feeling a little disappointed, since its shares fell 8.3% to US$12.76 in the week after its latest quarterly results. Revenue
Enanta Pharmaceuticals | 10-Q: Quarterly report
Hold Rating on Enanta Pharmaceuticals Amidst Clinical Trials Uncertainty and Financial Outlook
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Enanta Pharmaceuticals Is Maintained at Market Outperform by JMP Securities
Buy Rating Affirmed for Enanta Pharmaceuticals Amidst Promising RSV Developments and Clinical Trial Execution
Comments
Enanta Pharmaceuticals' P/S ratio remains low despite recent share price jump, likely due to weak revenue forecast. Market sentiment doesn't anticipate a strong share price rise soon.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth 1
Analysts hold a pessimistic view on Enanta Pharmaceuticals after its earnings shortfall. The consensus price target dropped significantly, suggesting lower earnings per share are a key indicator for the company's valuation. The company's long-term prospects are deemed more crucial than next year's earnings.
The low P/S ratio of Enanta Pharmaceuticals may be justified by its declining revenue and poor growth outlook compared to the industry. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.
Recent insider sale at Enanta Pharmaceuticals reflects possible contentment with lower company valuation. The absence of insider buying over past year raises caution for potential investors.
Upgrades
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
• $A.O. Smith(AOS.US$ : Longbow Research Upgrades to Buy from Neutral - PT $71
• $Callon Petroleum(CPE.US$ : RBC Upgrades to Outperform from Sector Perform - PT $75
• $Dun & Bradstreet(DNB.US$ : BofA Securities Upgrades to Neutral from Underperform - PT $17 (from $16)
• $Enanta Pharmaceuticals(ENTA.US$ : Evercore ISI Upgrades to Outperform from In Line - PT $62 (from $39)
• $Corning(GLW.US$ : CFRA Upgrades to Strong Buy ...
8
Read more